P53 mutation predicts intravesical adriamycin instillation failure in superficial transitional cell carcinoma of bladder.

Abstract

BACKGROUND:

We studied whether p53 status has any predictive value on the outcome of intravesical adriamycin (ADR) instillation for superficial transitional cell carcinoma (TCC) of the bladder.

MATERIALS AND METHODS:

Paraffin-embedded specimens were obtained from 70 consecutive patients by transurethral resection (TUR). All patients received intravesical instillation with either Epirubicin (n = 45) or Pirarubicin (n = 25). P53 mutation and overexpression were examined for single-strand conformation polymorphism (SSCP) and immunohistochemistry (IHC), respectively.

RESULTS:

In 18.2% of tumors, mutation was observed, including exon 5, 6 or 7. P53 overexpression was observed in 22.9% of tumors. High concordance between SSCP and IHC was shown (p = 0.0001), while there was a certain number of discrepant cases. The recurrence-free rate was significantly different between the group with and without p53 mutation, but not stage, grade or p53 IHC.

CONCLUSION:

P53 mutation predicts the failure of intravesical ADR instillation. Aggressive therapeutic approaches following initial TUR should be considered for patients with p53 mutation.

• Authors: Koji Shiraishi, Satoshi Eguchi, Jun Mohri, Yoriaki Kamiryo
• Journal: Anticancer research (Anticancer Res) 2003 Jul-Aug Vol. 23 Issue 4 Pg. 3475-8 ISSN: 0250-7005 [Print] Greece
• PMID: 12926093 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibiotics, Antineoplastic
• Tumor Suppressor Protein p53
• Doxorubicin

Topics

• Administration, Intravesical
• Adult
• Aged
• Aged, 80 and over
• Antibiotics, Antineoplastic (administration & dosage)
• Carcinoma, Transitional Cell (drug therapy, genetics, metabolism)
• Disease-Free Survival
• Doxorubicin (administration & dosage)
• Female
• Humans
• Immunohistochemistry
• Male
• Middle Aged
• Mutation
• Polymorphism, Single-Stranded Conformational
• Tumor Suppressor Protein p53 (biosynthesis, genetics)
• Urinary Bladder Neoplasms (drug therapy, genetics, metabolism)